Renerve (ASX:RNV) Other Long-Term Liabilities: A$0.00 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Renerve Other Long-Term Liabilities?

Renerve ASX:RNV +8.82% Other Long-Term Liabilities is A$0.00 Mil as of Jun. 2026. The stock has 5 warning signs investors should review.

Renerve's other long-term liabilities for the quarter that ended in Jun. 2026 was A$0.00 Mil.

Renerve's quarterly other long-term liabilities increased from Jun. 2025 (A$0.00 Mil) to Dec. 2025 (A$0.01 Mil) but then declined from Dec. 2025 (A$0.01 Mil) to Jun. 2026 (A$0.00 Mil).

Renerve's annual other long-term liabilities increased from Jun. 2024 (A$0.00 Mil) to Jun. 2025 (A$0.00 Mil) and increased from Jun. 2025 (A$0.00 Mil) to Jun. 2026 (A$0.00 Mil).

Renerve Other Long-Term Liabilities Related Terms

Renerve Other Long-Term Liabilities Historical Data

* Premium members only.

The historical data trend for Renerve's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Renerve Other Long-Term Liabilities Chart

Renerve Annual Data
Trend Jun22 Jun23 Jun24 Jun25 Jun26
Other Long-Term Liabilities
0.00 0.00 0.00 0.00 0.00

Renerve Semi-Annual Data
Jun22 Jun23 Jun24 Dec24 Jun25 Dec25 Jun26
Other Long-Term Liabilities Get a 7-Day Free Trial 0.00 0.04 0.00 0.01 0.00

Renerve Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

What does a Other Long-Term Liabilities of A$0.00 Mil mean?
Renerve (ASX:RNV) has a Other Long-Term Liabilities of A$0.00 Mil as of Jun. 2026. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Renerve and its competitors.
Is Renerve's Other Long-Term Liabilities too high?
Renerve's current Other Long-Term Liabilities is A$0.00 Mil.
How does Renerve's Other Long-Term Liabilities compare to VRTX and REGN?
Renerve's Other Long-Term Liabilities of A$0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Long-Term Liabilities for a Biotechnology company?
A good Other Long-Term Liabilities depends on the Biotechnology industry context. However, Other Long-Term Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Long-Term Liabilities mean?
A high Other Long-Term Liabilities can signal that a stock is expensive relative to its fundamentals. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Renerve and its competitors. Renerve's current Other Long-Term Liabilities is A$0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Renerve stock overvalued right now?
Renerve (ASX:RNV) has a current Other Long-Term Liabilities of A$0.00 Mil. The current Other Long-Term Liabilities is A$0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Long-Term Liabilities calculated?
Other Long-Term Liabilities is calculated from a company's financial statements. For Renerve (ASX:RNV), the current Other Long-Term Liabilities is A$0.00 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Renerve Business Description

Address 157 Heidelberg Road, Northcote, VIC, AUS, 3070
Renerve Ltd specializes in developing a range of ready-to-use products that are cleaner, safer for repairing or replacing damaged peripheral nerves, resulting in good patient outcomes. Its product candidates include NervAlign Bionic Nerve, NervAlign Nerve Graft, and NervAlign Nerve Cuff [The NervAlign Nerve Guide Matrix, The NervAlign Nerve Conduit, The NervAlign Bionic Replacement Nerve]. The company operates in New Zealand and USA. Maximum of revenue is from USA.